The activated hepatic stellate cells (aHSCs) in TME have been identified to promote cancer development.[201] Exosomes derived from CRCs induce HSCs to secrete excess IL‐6, which activates the IL‐6/STAT3 pathway to enhance lactate metabolism in CRCs and upregulates the expression of monocarboxylate transporters 1 (MCT1) and lactate dehydrogenase B (LDHB), thereby conferring resistance to irinotecan.[202]. This evidence concerns the gene IL6 and cancer.